Talazoparib and Avelumab in Participants With Metastatic Renal Cell Carcinoma
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Fumarate Hydratase Deficient Renal Cell Carcinoma
- Metastatic Renal Cell Carcinoma
- Succinate Dehydrogenase Deficient Renal Cell Carcinoma
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: Non-RandomizedIntervention Model: Single Group AssignmentIntervention Model Description: This is a phase II, open-label, single-institution trial.This is a phase II, open-label, single institution clinical trial of combination talazoparib and avelumab in patients with metastatic RCC. This clinical trial will enroll two separate cohorts in parallel.Masking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04068831
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Ritesh Kotecha, MD Memorial Sloan Kettering Cancer Center